Neurocrine is committed to transparency in its interactions. Neurocrine commits to following relevant pharmaceutical codes and has published details of its transfers of value below. Where individual countries have other transparency regulations, Neurocrine's declarations for these can be found in the Transparency dropdown menu on a country-specific basis. Disclosures prior to 2025 are reported under the legacy name Diurnal.
Neurocrine is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website www.clinicaltrials.gov
This site is for Non-UK Healthcare Professionals. By clicking you are acknowledging that you are a Non-UK Healthcare Professional